📅 PUBMED DAILY TRIAGE — 2026-05-27 (Wednesday)

Window: 2026-05-26T09:00:00Z → 2026-05-27T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~97 candidates | Candidates evaluated: 97 High priority: 4 | Standard: 12 | Low/archive: 0 | Unsolicited finds: 2 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (liquid biopsy, ctDNA, cfDNA)

TR-2026-05-27-001 / PMID 42192203 · NeoCircle: pre- and post-operative circulating tumor DNA dynamics predicts survival in neoadjuvant-treated early breast cancer · 9/10 · 🔴 EARLY_CANCER_DETECTION
→ Prospective cohort (n=136, SCAN-B) validating SV-based personalized ctDNA monitoring: end-NAT ctDNA positivity outperforms pCR for predicting relapse; post-op ctDNA has 13.8-month MRD lead time — EMBO Mol Med (Saal LH, Lund)

TR-2026-05-27-002 / PMID 42191070 · Compound EGFR mutations are predominantly PACC mutations with increased responsiveness to second- vs third-generation TKIs · 8/10 · 🟠 NOVEL_TREATMENT
→ Large-scale cfDNA characterization (n=15,851 samples + 1,542 clinical): PACC compound mutations (9% of EGFR-mutant NSCLC) retain same second-gen TKI superiority as single PACC; directly actionable treatment selection — J Thorac Oncol (MD Anderson/Guardant)

Novel Therapeutics: immunotherapy, CAR-T, targeted therapy

TR-2026-05-27-003 / PMID 42192224 · PAPILLON Phase 3 China subgroup: amivantamab + chemotherapy vs chemotherapy for EGFR exon 20 insertion NSCLC · 8/10 · 🟠 NOVEL_TREATMENT
→ Phase 3 RCT subgroup (n=87 Chinese patients): mPFS 12.3 vs 6.7 months (HR 0.47), ORR 71.8% vs 48.9% — consistent with global PAPILLON; supports first-line amivantamab in Chinese patients — Chin Med J (Tang K/Zhou C)

Rare Diseases with High Unmet Need

TR-2026-05-27-004 / PMID 42191456 · EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE
→ Joint EASL-AASLD Delphi (62 panelists, 88% response): 16 consensus statements + 42 recommendations to unblock regulatory pathway for 3 conditionally approved PBC therapies — J Hepatol (Levy C/Lleo A)

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

• TR-2026-05-27-005 / PMID 42191947 · Optimized PET/CT response assessment in extranodal NK/T-Cell lymphoma (n=259) · 7/10 · Diagnostics — Novel IPN criteria outperform Lugano classification; highest C-index for PFS+OS in ENKTL
• TR-2026-05-27-006 / PMID 42190708 · Next-generation immunotherapies in multiple myeloma (JNCCN review, MSK) · 7/10 · Treatment Innovation — Comprehensive coverage of 6 FDA-approved CAR-T/BsAb agents + frontline trial landscape
• TR-2026-05-27-007 / PMID 42190411 · PCR-MRD in pediatric KMT2A-r AML (n=46) · 7/10 · Diagnostics — EOC1 PCR-MRD positivity independently predicts inferior OS/LFS/CIR; supports allo-HSCT risk stratification

Early Cancer Detection (liquid biopsy, ctDNA, cfDNA)

• TR-2026-05-27-008 / PMID 42192045 · cfDNA ERBB2 CN change predicts outcomes in HER2+ gastric cancer phase II (n=55) · 7/10 · Diagnostics — Longitudinal ΔCN independently prognostic in multivariable analysis; ddPCR approach robust
• TR-2026-05-27-015 / PMID 42190398 · French GFCO ctDNA technical Delphi consensus (39 platforms, 37 recommendations) · 6/10 · Diagnostics — Largest EU ctDNA standardization effort; mandatory UMI + CHIP reporting framework

AI/ML in Clinical Diagnostics and Imaging

• TR-2026-05-27-009 / PMID 42191361 · AI-POCUS carotid plaque detection by GPs after training (n=169, Ann Fam Med) · 7/10 · Diagnostics — Sensitivity 87%, specificity 91%, κ=0.78; scalable primary care CV screening model

Novel Therapeutics

• TR-2026-05-27-010 / PMID 42190521 · Older mTNBC real-world outcomes vs younger: ESME cohort (n=4,246) · 7/10 · Public Health / UNDERSERVED — Comparable OS despite treatment disparities; older women underrepresented in trials
• TR-2026-05-27-011 / PMID 42190397 · TP53/KRAS co-mutation identifies poor-prognosis BTC subset after ICI+chemo (n=1,875) · 7/10 · Genomics/Precision Medicine — C-CAT national Japan database; hypothesis-generating negative ICI biomarker

Cardiovascular-Metabolic

• TR-2026-05-27-012 / PMID 42191874 · SGLT2i meta-analysis: reductions in epicardial adipose tissue (n=284, 11 studies) · 7/10 · Treatment Innovation — Consistent EAT reduction across modalities; novel CV benefit mechanism
• TR-2026-05-27-013 / PMID 42192214 · CSVD in Latin American dementia cohort (n=1,675, 6 countries) · 7/10 · Prevention / UNDERSERVED — First large LatAm CSVD study; HTN/smoking strongest WMH correlates; Alzheimer's & Dementia

Aging/Longevity

• TR-2026-05-27-016 / PMID 42191913 · Essential trace elements, dietary patterns, and biological aging (n=2,627 older adults) · 6/10 · Prevention — Se dominant contributor to decelerated biological age; high-protein + plant-based diets protective

💡 UNSOLICITED FINDS

• TR-2026-05-27-014 / PMID 42192211 · Synaptic biomarkers in Alzheimer's disease and MCI: meta-analysis of 65 cohorts · 7/10 · Diagnostics — 8 CSF + 3 blood synaptic biomarkers (SNAP-25, GAP-43 most robust) validated across 65 cohorts; Alzheimer's & Dementia; translational relevance for non-invasive AD diagnostics

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 6 articles (001, 003, 004, 006, 010, 012)
• Diagnostics: 6 articles (005, 007, 008, 009, 014, 015)
• Early Detection: 1 article (001 — cross-listed)
• Genomics/Precision Medicine: 2 articles (002, 011)
• Prevention: 3 articles (009, 013, 016)
• Public Health: 1 article (010)

By evidence maturity:

• Validated: 14 articles
• Exploratory: 2 articles (011, 016)

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed 16 | preprint 0

Topics with zero 8+ articles this run:

• Hematologic malignancies (best: 7/10 — ENKTL PET/CT, MM immunotherapy review)
• CBC-based diagnostics and ML in hematology (best: 4/10 — ⚠️ 11th+ consecutive sparse run)
• AI/ML in clinical diagnostics and imaging (best: 7/10 — AI-POCUS carotid screening)
• Precision oncology and genomic medicine (best: 7/10 — BTC TP53/KRAS co-mutation)
• Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk (best: 7/10 — SGLT2i EAT meta-analysis; no GLP-1/semaglutide-specific high-yield articles today)
• Aging, longevity, and population health (best: 6/10 — trace elements biological aging)

🔧 RUN NOTES

• Window expansion: Not triggered (≥5 relevant records found in primary 24h window)
• Truncation: Sentinel scan raw count 1277 — capped at 10 candidates per protocol; Novel therapeutics raw count 51, Cardiometabolic 52, both reviewed top 10
• humans[MeSH] filter: Applied to Aging/longevity per v1.2 refinement note; successfully reduced non-human biology noise (vs 56 results + pest management hits documented in 2026-05-04 run)
• CBC/ML hematology (11th+ consecutive sparse run): This topic consistently fails to produce watchlist-relevant articles. Raw query returns 20-30 results but all were tangential (hemorrhage/hematoma MeSH expansions, food AI, non-hematology ML). Consider watchlist query revision for this topic at next schema review.
• Deferred PMID 42185479 (Nat Cancer CNS leukemia copper, from 2026-05-26): Remains deferred. Non-human model constraints applied in prior run. Phase 2 full-text review recommended.
• Rolling 7-day zero-HIGH topics: CBC/ML hematology (persistent 11+ run gap); AI/ML diagnostics (5th+ consecutive run without 8+); Cardiometabolic (2nd consecutive no 8+)
• COI note: PMID 42192203 (NeoCircle) has commercial COI — several co-authors are co-founders/employees of SAGA Diagnostics (ctDNA company). Study design is prospective with sponsor independence noted; flag for Phase 2 COI evaluation.